Updates in Combination Therapy for HCC

Yale Cancer Center

S. Stein

ASCO® GI 2024 Summary: "HCC Key Studies Including EMERALD-1 & IMbrav…

Insights from 2024 ASCO® GI Annual Meeting

R. Kim, T. Biachi

Understanding HCC: Perspectives on Diagnosis, Risk Factors, and Trea…

Yale Cancer Center

A. Jaffe

ACG 2023 Highlights: HCC Updates - Diagnosis and Management

ACG 2023 Conference Coverage

R. Wong

Expert Panel on TACE and TARE for HCC: Weighing the Pros and Cons

Integrity CE

M. Pishvaian, R. Salem

GI Oncology Year in Review: Hepatobiliary Cancers

Yale Cancer Center

P. Kunz

Treatment Approaches in Bone Metastases Pain Management

Francesco Massari

Management of Toxicity and Dose Modification Associated With Cabozan…

Cedars Sinai

J. Gong

Systemic Treatment Landscape for Advanced HCC: Case Discussion - 40 …

The France Foundation

A. Burgoyne, S. Stein

Hepatic Arterial Infusion for Primary Liver Cancer

Integrity CE

K. Lafaro

Advancements in Systemic Therapy for Advanced HCC: Where Are We Going

Johns Hopkins

M. Yarchoan

Expert Panel on Choosing Systemic vs. Locoregional Therapy in HCC

Integrity CE

M. Pishvaian, A. Singal, R. Finn, R. Salem

How to Incorporate Molecular Testing in Therapy for Localized Cholan…

Flavio Rocha

Year in Review: Gastric, Esophageal, & Liver Cancers

OncoAlert

S. Gill

ASCO GI 2023 NRG/RTOG 1112 Randomized Phase 3 Study: Sorafenib vs. S…

ASCO GI 2023 Conference Coverage

L. Dawson

Updates in Radiation Therapy for GI Cancers

Total Health

N. Sanford

Common TKI Toxicity Management in 2L HCC Treatment

NYU Langone

J. Wu

ASCO® 2023 Insights: "Randomized, Double-Blind, Placebo-Controlled D…

Insights from 2023 ASCO® Annual Meeting

A. Batra

Considerations for 1L Treatment Selection in Advanced HCC: Safety an…

Yale Cancer Center

S. Stein

Medical Oncology Updates in Unresectable HCC: Where Are We and Where…

2023 Johns Hopkins Updates in Gastrointestinal Cancers

D. Li